Abstract |
The present study was undertaken to investigate the efficacy of a new, highly purified (purity greater than 91%), ethyl esterification product from natural eicosapentaenoic acid (EPA-E, C20:5 omega 3) in patients with type II diabetes mellitus ( NIDDM). Hemodynamic changes were assessed at the level of the dorsalis pedis artery using an ultrasonic color Doppler duplex system before and after oral administration of EPA-E at a dose of 1800 mg/day for 48 weeks. The cross-sectional area of the dorsalis pedis artery increased significantly from 2.5 +/- 0.2 to 3.9 +/- 0.4 mm2 (48 weeks, mean +/- SE, p < 0.05). Moreover, EPA-E improved the clinical symptom (coldness, numbness) as well as the vibration perception threshold sense of the lower extremities [from 32.1 +/- 8.5 to 16.1 +/- 4.8 (48 weeks) microns]. A significant decrease of serum triglycerides was also noted by EPA-E administration. Furthermore, significant decrease of the excretion of albumin in urine [from 24.4 +/- 3.3 to 13.9 +/- 1.8 (48 weeks) mg/g.Cr, p < 0.05]. The results of this study suggest that EPA-E has significant beneficial effects on diabetic neuropathy and serum lipids as well as other diabetic complications such as nephropathy and macroangiopathy.
|
Authors | Y Okuda, M Mizutani, M Ogawa, H Sone, M Asano, Y Asakura, M Isaka, S Suzuki, Y Kawakami, J B Field, K Yamashita |
Journal | Journal of diabetes and its complications
(J Diabetes Complications)
1996 Sep-Oct
Vol. 10
Issue 5
Pg. 280-7
ISSN: 1056-8727 [Print] United States |
PMID | 8887017
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Fatty Acids, Unsaturated
- Lipoproteins
- Eicosapentaenoic Acid
|
Topics |
- Adult
- Aged
- Diabetes Mellitus, Type 2
(complications, drug therapy, physiopathology)
- Diabetic Neuropathies
(drug therapy, physiopathology)
- Eicosapentaenoic Acid
(therapeutic use)
- Fatty Acids, Unsaturated
(blood)
- Female
- Hemodynamics
- Humans
- Lipoproteins
(blood, drug effects, metabolism)
- Male
- Middle Aged
- Time Factors
|